Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
Danielle Rodin, MD, MPH, FRCPC, is a radiation oncologist at Princess Margaret Cancer Centre and an Assistant Professor in the Department of Radiation Oncology at the University of Toronto. She is the Director of the Global Cancer Program at Princess Margaret Cancer Centre and was elected to the Board of Directors for the Union for International Cancer Control (UICC) in Geneva. Her clinical interests are in breast cancer and hematologic malignancies. She is a health services researcher, with interests in health technology assessment, global health systems, and large database analyses of cost and quality in cancer care. Dr. Rodin received her B.A.(Hons.) from McGill University, her medical degree from the University of Toronto, and her Master of Public Health from Harvard University, and was the 2017-2018 Canadian Harkness Fellow in Health Care Policy and Practice in the Department of Health Policy and Management at the Harvard T. H. Chan School of Public Health.
Dr. Meredith Giuliani is an Associate Professor in the Department of Radiation Oncology at the University of Toronto and a radiation oncologist at the Princess Margaret Cancer Centre. She received her MBBS qualification from the University of London, England and her Master of Education from the University of Toronto. She completed her residency training a the University of Toronto. She is the Chair of the Canadian Association of Radiation Oncology's Education Committee, the Medical Director of Education for Princess Margaret Cancer Centre, the Director of Undergraduate Medical Education for the Department of Radiation Oncology at the University of Toronto and the Cancer Care Ontario Smoking Cessation Champion for Toronto Central South. Her research interests include the influence of globalization on education with a focus on curriculum design and implementation. Her clinical interests are in lung and head and neck cancers.
Anet Julius completed her Master of Nursing at the University of Toronto in 2011, and has been an Advanced Practice Nurse Educator at the Princess Margaret for the inpatient medical radiation, palliative care, and short stay units since 2012. She tool on the role of interim Senior Professional Practice Leader at the Princess Margaret in 2017 and is currently the Interim Director of Professional Practice.
Anet has been involved in various initiatives to improve patient care and nursing practice at UHN.
She holds an Adjunct Lecturer appointment with the Lawrence S. Bloomberg Faculty of Nursing, University of Toronto. Anet has also been a frequent lecturer for UHN-Princess Margaret's International program teaching the Specialized Oncology Nursing Curriculum in Kuwait and Qatar.
Lesley Chalklin, MSc, PMP, is a Program Manager for the Princess Margaret Global Cancer Program and the Program Manager for the Global Institute of Psychosocial, Palliative and End-of-Life Care (GIPPEC), a research institute of the Princess Margaret and the University of Toronto. Lesley completed her Master's of Health Administration and has her Project Management Professional (PMP) designation. Prior to joining the program, Lesley acted as the Program Manager for the Adolescent and Young Adult Program and the Older Adults with Cancer Clinic at the Princess Margaret. Lesley has led projects within the health sector for over five years.
Dr. Mathieu Lupien is a senior scientist at the Princess Margaret Cancer Centre and is an associate professor in the Department of Medical Biophysics at the University of Toronto. He also has a cross-appointment with the Ontario Institute for Cancer Research (OICR). He earned his PhD at McGill University in 2005 and was an Era of Hope fellow at the Dana-Farber Cancer Institute, Harvard Medical School.
Dr. Lupien is recognized for his contribution to the field of cancer epigenetics and for demonstrating the role of the noncoding genome in cancer development. Among other honours, Dr. Lupien is a two-time recipient of the Investigator Award from the OICR, the Till and McCulloch Discovery of the Year award, the Rising Star in Prostate Cancer Research award from PCC/Movember, and the Canadian Cancer Society Bernard and Francine Dorval Award for Excellence.
Meena Merali is the Director of Cancer Strategy Stewardship at Princess Margaret Cancer Centre. She is a results-driven healthcare leader with a track record of building strong relationships and partnerships on a local, national, and global scale. Meena has led sustainable and culturally congruent international programs to build capacity, improve access to cancer care, and advocate for global cancer control. In her current role, she provides leadership and oversight to catalyze progress towards strategic goals while measuring and maximizing the impact of philanthropic dollars to accelerate cancer research, education and clinical care.
Meena is a Professional Engineer with a Bachelor of Applied Science in Chemical Engineering from the University of Waterloo and a Master of Business Administration from Ivey Business School at Western University.
Dr. Yasufuku is Associate Professor of Surgery at the University of Toronto, Staff Thoracic Surgeon at the Division of Thoracic Surgery, and Director of the Interventional Thoracic Surgery Program at the University Health Network (UHN) with special interest in minimally invasive diagnostics and therapeutics. He is the clinical lead of Thoracic Surgery within the Guided Therapeutics Program and of the Thoracic Robotic Surgery Program at UHN. He is a Scientist at the Latner Thoracic Surgery Research Laboratory, Toronto General Hospital Research Institute, University Health Network and his research interests include development of new technology in early diagnosis and ultra minimally invasive thoracic surgery, translational research in thoracic image-guided therapeutics (GTx), nanotechnology enabled image-guided intervention for lung cancer and molecular profiling of advanced stage lung cancer by minimally invasive procedures.
Natasha Leighl, MD, is a professor in the Department of Medicine at the University of Toronto. She is also lung site lead in the Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre/University Health Network, as well as the OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development at Princess Margaret Cancer Foundation. She is a member of the Lung Site Executive of the Canadian Cancer Trials Group (CCTG, formerly NCIC CTG).
Dr. Leighl has authored or coauthored more than 200 articles in high-impact journals. She is co-editor of the Lung Section of the Oncologist, the Pharmacoeconomic Section of Current Oncology and is on the editorial board of the Journal of Thoracic Oncology (formerly Web Editor). She is co-chair of the Committee on Economic Analysis and past President of Lung Cancer Canada.
Dr. Al-Awamer is a native Saudi Arabian and obtained his medical degree at King Faisal University. He completed residency training in family medicine and palliative medicine and a Master of Health Science degree in bioethics at the University of Toronto.
He is an Assistant Professor in the Department of Family and Community Medicine at the University of Toronto, a staff Palliative Care Physician and educator in the Department of Supportive Care, Princess Margaret Cancer Centre. Dr. Al-Awamer is the Co-Director of the Palliative Medicine Clinical Fellowship Program. Dr. Al-Awamer's research interests include advancing palliative care globally, models to provide palliative care for adolescents and young adults, medical education and curriculum development, and end of life ethics. He has published and delivered conference papers nationally and internationally about palliative care and ethics.
After graduating from Sheffield University and completing her radiation oncology residency at Queen's University, Dr. Rebecca Wong joined the Princess Margaret. She holds an MSc in Clinical Epidemiology from McMaster University. Currently, she is a Professor in the Department of Radiation Oncology at the University of Toronto and the Director of the Clinical Trials Program for Radiation Medicine at the Princess Margaret.
Her clinical and research interests are aimed at improving the outcomes of patients with gastroesophageal cancer and patients living with metastatic cancer, including oligometastases. Her specific focus in this area examines the use of radiotherapy through clinical trials, knowledge synthesis and guidelines development. She is active in evidence-based guidelines development through her role as Co-Chair for the gastrointestinal disease site group in the Cancer Care Ontario Practice Guideline Initiative. She is also the author of over 100 peer-reviewed publications and 8 book chapters.
Michael Milosevic is a radiation oncologist at the Princess Margaret Cancer Centre and a Professor of Radiation Oncology at the University of Toronto. He is also Vice-Chair of Research in the Department of Radiation Oncology, a Past President of the Canadian Association of Radiation Oncology (CARO) and the founding Chair of the Canadian Partnership for Quality in Radiotherapy (CPQR).
Dr. Milosevic's clinical practice is focused on gynecological cancers. His primary research interests are in high precision, MR-guided external beam radiotherapy and brachytherapy, and biological targeting of tumour hypoxia and immune-mediated radiation treatment resistance. Dr. Milosevic is committed to building radiation treatment capacity in developing parts of the world where gynecological cancers are amongst the most common and devastating diseases.
Dr. Milosevic received his MD at Queen's University and completed his training in radiation oncology at the University of Toronto.
Dr. Anna Dare is a general surgery Chief Resident in the Department of Surgery, University of Toronto, and an epidemiologist at the Centre for Global Health Research, St. Michael's Hospital. Her areas of interest are in quantifying the burden of surgical conditions globally, and relating this to access to surgical care using epidemiological, geostatistical and econometric approaches. Anna served as a Commissioner on the Lancet Commission on Global Surgery and the Lancet Oncology Commission on Cancer Surgery, led the Disease Control Priorities-3 chapter on Surgical Services for Cancer Care and is the Canadian National Lead for the GlobalSurg3 study evaluating access, quality and outcomes following breast, colorectal and gastric cancer surgery in 84 countries. A native of New Zealand, she has also lived and worked in the United Kingdom, Nepal, India, Sierra Leone and Canada.
Dr. Krzyzanowska is a practising medical oncologist and a health services researcher at Princess Margaret Cancer Centre in Toronto. The overarching goal of her research program is to improve the quality of care received by cancer patients. She combines patient-level studies focusing on specific quality issues in the oncology population such as drug safety and toxicity with population-based research. This approach allows her to look at quality issues from different, but complementary perspectives. Her studies have had an impact at both the hospital and population levels. Dr. Krzyzanowska obtained her medical degree and clinical training at the University of Toronto and completed a research fellowship at the Centre for Outcomes and Policy Research at the Dana Farber Cancer Institute in Boston. In addition to her clinical and research work, she holds leadership positions related to quality of cancer care at the local, provincial and international levels.
Dr. Mary Gospodarowicz is a radiation oncologist at the Princess Margaret Cancer Centre and a Professor at the University of Toronto. She is the Associate Editor of Cancer Biology & Medicine and the Journal of Global Oncology.
Professor Gospodarowicz is a Fellow of the American Society for Radiation Oncology (ASTRO), an honorary fellow of the Royal College of Radiologists, and an honorary member of the European Society for Radiotherapy & Oncology (ESTRO), the German Society for Radiation Oncology (DEGRO), and the Scientific Association of Swiss Radiation Oncology (SASRO). She was the President of the Union for International Cancer Control (UICC) from 2012 to 2014, and chairs the TNM Prognostic Factors Project at UICC. She has received the ASTRO Gold Medal, the American Radium Society Janeway Medal, the O. Harold Warwick Prize from the Canadian Cancer Society, and the Women Who Conquer Cancer Mentorship Award from the American Society of Clinical Oncology. She was appointed Officer of the Order of Canada in 2015.
Dr. Michael Baumann is a physician, radiation oncologist and radiation biologist who has treated cancer patients by radiation therapy since 1990. From 2004 to 2016, he established the OncoRay National Center for Radiation Research in Oncology in Dresden and pursued the integration of new biological findings with advanced technologies in radiation therapy.
Since November 2016, Baumann has been Chairman and Scientific Director of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) in Heidelberg and chairman and spokesperson of the steering committee of the German Cancer Consortium (DKTK). His own research focus is on individualized radiotherapy, where radiation-specific biomarkers are used to adjust radiation treatment to the individual patient.
Michael Baumann earned his degree as a medical doctor from Hamburg University in 1988. He went on to work as a postdoctoral fellow at Massachusetts General Hospital at Harvard Medical School.
Dr. Patrick Loehrer is a medical oncologist specializing in cancers of the testis, bladder, colon, pancreas, and thymus gland. He is Director of the Indiana University Melvin and Bren Simon Cancer Center, an IU Distinguished Professor, H.H. Gregg Professor of Oncology, and Associate Dean for Cancer Research at Indiana University School of Medicine. Dr. Loehrer is a past member and/or chair of numerous ASCO committees, including the Cancer Communications Committee, Career Development Committee, Professional Development Committee, Annual Meeting Education Committee and Leadership Development Program, and served as a member of the ASCO Board of Directors from 1998-2001. In 2017, Dr. Loehrer received the inaugural Allen S. Lichter Visionary Leader Award from ASCO for his extraordinary leadership.
Dr. Loehrer received his medical degree from Rush Medical College in 1978. He completed his internship and residency at Rush Presbyterian St. Luke's Medical Center and a fellowship in medical oncology at Indiana University. In 1983, he joined the faculty of IU School of Medicine.
Felicia Knaul is the Director of the Miami Institute for the Americas at the University of Miami College of Arts & Sciences, which focuses on policy analysis in all sectors, including the humanities, the arts, and social and economic development. She is also a Professor in the Department of Public Health Sciences at the University of Miami Miller School of Medicine.
Since 2014, Dr. Knaul has been the Chair of the Lancet Commission on Global Access to Palliative Care and Pain Control.
As a result of her breast cancer experience, in 2008 she founded Cancer de Mama: Tomatelo a Pecho, a non-profit agency in Mexico that promotes research, advocacy, awareness, and early detection throughout Latin America.
Dr. Knaul has produced more than 170 academic and policy publications, authored and lead-edited academic books, and serves on the advisory board or editorial board of several medical and health care publishers. She received her PhD and M.A. in economics from Harvard University.
Richard Sullivan is a Professor of Cancer and Global Health at King's College London, and Director of the Institute of Cancer Policy (ICP) and co-Director of the Conflict and Health Research Group. As well as holding a number of Visiting Chairs, Richard is an NCD advisor to the WHO, civil-military advisor to Save the Children, and a member of the National Cancer Grid of India. His research focuses on global cancer policy and planning, and health systems strengthening, particularly conflict ecosystems. Richard has led five Lancet Oncology Commissions and worked on 4 others. He is currently co-leading Lancet Oncology commissions on the Future of Cancer Research in Europe and Cancer Care in Conflict.
Professor Sullivan qualified in medicine and trained in surgery (urology), gaining his PhD from University College London. He was also clinical director of Cancer Research UK between 1999 and 2008. Following a period at the London School of Economics, working on complex healthcare systems, he moved to King's College London in 2011.
Dr. C.S. Pramesh is the Professor and Head of Thoracic Surgery and Convener of the Thoracic Oncology Disease Management Group at the Tata Memorial Centre, Mumbai. He is the coordinator for the National Cancer Grid, the largest network of major cancer centres in India. The mandate of the National Cancer Grid is primarily to provide uniform standards of cancer care across the country. Dr. Pramesh is highly committed to efforts towards reducing inequities in cancer care and making cancer treatment accessible to all geographic regions and strata of society.
His primary clinical areas of interest include the treatment of esophageal and lung cancers and minimally invasive surgery. He has written more than 140 peer-reviewed journal articles, abstracts and book chapters on topics in his specialty, including esophageal and lung cancers, minimally invasive surgery, tracheal, mediastinal and chest wall tumours, clinical research methods, translational research and cancer policy.